PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-100.00%
Negative revenue growth while Biotechnology median is 0.00%. Seth Klarman would investigate if the company is losing market share or facing a declining industry.
-83.05%
Negative gross profit growth while Biotechnology median is -0.02%. Seth Klarman would suspect poor product pricing or inefficient production.
7.21%
EBIT growth exceeding 1.5x Biotechnology median of 1.84%. Joel Greenblatt would examine whether a unique competitive edge supports this outperformance.
7.21%
Operating income growth exceeding 1.5x Biotechnology median of 1.54%. Joel Greenblatt would see if unique processes drive exceptional profitability.
7.01%
Net income growth exceeding 1.5x Biotechnology median of 2.96%. Joel Greenblatt would check if brand strength or cost advantages fuel this outperformance.
8.82%
EPS growth near Biotechnology median of 9.01%. Charlie Munger might conclude it’s in line with industry norms.
8.82%
Diluted EPS growth near Biotechnology median of 8.82%. Charlie Munger would expect typical industry-level share usage and profit trends.
0.91%
Share growth above Biotechnology median by more than 2x. Jim Chanos would suspect over-dilution or repeated equity raises.
0.91%
Diluted share growth above 2x Biotechnology median. Jim Chanos would suspect undue issuance or heavy employee stock compensation.
No Data
No Data available this quarter, please select a different quarter.
1.55%
Positive OCF growth while Biotechnology median is negative. Peter Lynch might see a strong relative advantage in operational efficiency.
1.40%
Positive FCF growth while Biotechnology median is negative. Peter Lynch might view this as a notable advantage over peers.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Negative 3Y CAGR while Biotechnology median is 0.00%. Seth Klarman would examine if the sector is otherwise stable, indicating a company-specific issue.
91.07%
OCF/share CAGR of 91.07% while Biotechnology median is zero. Walter Schloss might see a modest edge that can add up if momentum improves.
81.18%
OCF/share CAGR of 81.18% while Biotechnology median is zero. Walter Schloss might see a slight advantage that can compound if momentum builds.
13.88%
3Y OCF/share growth of 13.88% while Biotechnology median is zero. Walter Schloss might see a modest advantage that could compound if momentum holds.
98.43%
Net income/share CAGR exceeding 1.5x Biotechnology median of 15.63% over a decade. Joel Greenblatt might see a standout compounder of earnings.
78.58%
5Y net income/share CAGR > 1.5x Biotechnology median of 19.61%. Joel Greenblatt might see superior mid-term capital allocation or product strength.
-7.39%
Negative 3Y CAGR while Biotechnology median is 21.52%. Seth Klarman might see a pressing concern if the rest of the sector is stable or growing.
109.82%
Equity/share CAGR of 109.82% while Biotechnology median is zero. Walter Schloss might see a modest advantage in net worth accumulation that could matter long term.
14.99%
5Y equity/share CAGR of 14.99% while Biotechnology median is zero. Walter Schloss sees a slight positive that might compound if management executes well.
-59.15%
Negative 3Y equity/share growth while Biotechnology median is -35.99%. Seth Klarman sees a short-term weakness if peers still expand net worth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
8.48%
We expand assets while Biotechnology is negative. Peter Lynch sees a possible advantage if expansions align with profitable markets or a recovering cycle.
19.47%
Positive BV/share change while Biotechnology median is negative. Peter Lynch finds a strong advantage vs. peers failing to expand equity.
-6.20%
Debt is shrinking while Biotechnology median is rising. Seth Klarman might see an advantage if growth remains possible.
-18.94%
R&D dropping while Biotechnology median is rising. Seth Klarman wonders if we risk ceding future innovation or if peers overspend.
28.45%
SG&A growth far above Biotechnology median. Jim Chanos sees potential red flags in cost management or diminishing returns on spending.